CSL Limited 2025-06-30 CSL Limited 2024-07-012025-06-30 CSL Limited 2024-07-012025-06-30 Austria CSL Limited 2025-06-30 Austria CSL Limited 2024-07-012025-06-30 Belgium CSL Limited 2025-06-30 Belgium CSL Limited 2024-07-012025-06-30 Czech Republic CSL Limited 2025-06-30 Czech Republic CSL Limited 2024-07-012025-06-30 Denmark CSL Limited 2025-06-30 Denmark CSL Limited 2024-07-012025-06-30 Finland CSL Limited 2025-06-30 Finland CSL Limited 2024-07-012025-06-30 France CSL Limited 2025-06-30 France CSL Limited 2024-07-012025-06-30 Germany CSL Limited 2025-06-30 Germany CSL Limited 2024-07-012025-06-30 Greece CSL Limited 2025-06-30 Greece CSL Limited 2024-07-012025-06-30 Hungary CSL Limited 2025-06-30 Hungary CSL Limited 2024-07-012025-06-30 Ireland CSL Limited 2025-06-30 Ireland CSL Limited 2024-07-012025-06-30 Italy CSL Limited 2025-06-30 Italy CSL Limited 2024-07-012025-06-30 Netherlands CSL Limited 2025-06-30 Netherlands CSL Limited 2024-07-012025-06-30 Panama CSL Limited 2025-06-30 Panama CSL Limited 2024-07-012025-06-30 Poland CSL Limited 2025-06-30 Poland CSL Limited 2024-07-012025-06-30 Portugal CSL Limited 2025-06-30 Portugal CSL Limited 2024-07-012025-06-30 Romania CSL Limited 2025-06-30 Romania CSL Limited 2024-07-012025-06-30 Russia CSL Limited 2025-06-30 Russia CSL Limited 2024-07-012025-06-30 Slovakia CSL Limited 2025-06-30 Slovakia CSL Limited 2024-07-012025-06-30 Spain CSL Limited 2025-06-30 Spain CSL Limited 2024-07-012025-06-30 Sweden CSL Limited 2025-06-30 Sweden CSL Limited 2024-07-012025-06-30 Turkey CSL Limited 2025-06-30 Turkey iso4217:USD xbrli:pure

Public Country by Country Report (on income tax information)

Introduction

This report has been prepared to comply with the CSL Group’s European Union (EU) public Country-by-Country reporting requirements as enacted under relevant local legislation. The CSL Group includes CSL Ltd, an Australian Securities Exchange listed entity, and its controlled entities. This report provides FY25 jurisdictional information for the CSL Group, on a basis consistent with the prescribed EU reporting framework. It should be read in conjunction with CSL’s FY25 Annual Report (https://investors.csl.com/annualreport/2025/) and FY25 Tax Transparency Report (https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2024-25.pdf), which provide additional context on CSL’s operations, financial performance and tax profile.

Section 1. General information

Name of ultimate parent of group / of standalone companyCSL Limited
Country of registered office of ultimate parent undertakingThe Commonwealth of Australia
Date of start of financial year2024-07-01
Date of end of financial year2025-06-30
Reporting currencyUSD
Application of option to report in accordance with taxation reporting instructionsYes
Name and registered office of a single subsidiary undertaking which has published the report on income tax information of an undertaking that is not governed by the law of a Member StateCSL Behring S.p.A Viale del Ghisallo n.20 I-20151 MILANO Italy Seqirus S.r.l Via Fiorentina 1 53100 Siena Italy Vifor Pharma Italia S.r.l. Via Paolo Di Dono, 73 / 00142 Rome Vifor Fresenius Medical Care Renal Pharma Italia S.r.l. Largo Donegani 2 20121 Milan CSL Behring ApS Lyngby Hovedgade 70 A 1 2800 Lyngby Copenhagen Denmark CSL Behring s.r.o. Vyskocilova 2a 1461 BB Centrum Building Alpha 140 00 Prague Czech Republic
Name and address of a single branch which has published the report on income tax information of an undertaking that is not governed by the law of a Member StateN/A
Language of reportenglish - en

Section 2. Overview of information on a country-by-country basis

Name of Member State or tax jurisdiction Country code of Member State or tax jurisdiction Revenues Profit (loss) before tax Income tax paid (on cash basis) Income tax accrued – current year Accumulated earnings Number of employees
Austria AT 103732281 4791037 1301871 1175126 10104566 49
Belgium BE 224016660 13177212 3241031 3532249 57764640 48
Czech Republic CZ 51128484 2239524 515253 529053 10484638 14
Denmark DK 49107724 2611227 559275 607297 -269370310 11
Finland FI 1204140 57340 0 11468 232763 4
France FR 548987152 33534899 14956477 10174112 139247376 194
Germany DE 4790243272 407786908 84760739 135230373 3151549036 4231
Greece GR 22293444 -2854978 2053668 -825195 8879114 15
Hungary HU 47603147 1645133 116100 148043 9329743 112
Ireland IE 8981688 1099898 0 53274 0 8
Italy IT 440973869 42162053 13217963 17722103 153499258 167
Netherlands NL 390296557 6637309 1912459 1831752 35440712 82
Panama PA 35659763 1693128 180186 51553 17237453 7
Poland PL 83244272 4531584 829670 861001 12515939 23
Portugal PT 77704160 2681203 1253534 930537 27541787 29
Romania RO 13939263 654468 243086 242566 9275329 22
Russia RU 6283692 996578 730687 628393 3154657 68
Slovakia SK 1042420 87264 -11044 26607 236653 4
Spain ES 331396923 60888751 3765858 4354362 107583793 133
Sweden SE 235830341 13148828 2627069 2779414 86963387 59
Turkey TR 56337635 4066994 940570 846452 19240743 31
All other tax jurisdictions (aggregated basis)
30811266359 2868418059 505863790 599715317 40345628083 25296

Section 3. List of subsidiaries and activities

Name of Member State or tax jurisdictionCountry code of Member State or tax jurisdictionName of subsidiary undertakings consolidated in financial statements of ultimate parent undertakingBrief description per country of nature of activities in Member State or tax jurisdiction
Austria AT CSL Behring GmbH Vifor Pharma Österreich GmbH Sales, marketing and distribution Administrative and management service providers
Belgium BE CSL Behring NV Vifor Pharma België NV Vifor Fresenius Medical Care Renal Pharma België NV Sales, marketing and distribution Administrative and management service providers
Czech Republic CZ CSL Behring s.r.o. Sales, marketing and distribution
Denmark DK CSL Behring ApS Sales, marketing and distribution
Finland FI Vifor Pharma Nordiska AB - Finland branch Administrative and management service providers
France FR CSL Behring S.A. Vifor France S.A.S. Vifor Fresenius Medical Care Renal Pharma France S.A.S. Sales, marketing and distribution Administrative and management service providers
Germany DE CSL Behring GmbH CSL Plasma GmbH CSL Behring Beteiligungs und Verwaltungs GmbH & Co KG CSL Finance GmbH CSL Behring Holdings GmbH CSL Innovation GmbH CSL Behring Verwaltungs GmbH Seqirus GmbH Vifor Pharma Deutschland GmbH Fresenius Medical Care Nephrologica Deutschland GmbH Manufacturing Product ownership and development Sales, marketing and distribution Research and development Administrative and management service providers
Greece GR CSL Behring EPE Sales, marketing and distribution
Hungary HU CSL Plasma Kft CSL Behring Kft. Sales, marketing and distribution
Ireland IE Vifor Pharma UK Ltd. - Dublin branch Administrative and management service providers
Italy IT CSL Behring SpA Seqirus S.r.l Vifor Pharma Italia S.r.l. Vifor Fresenius Medical Care Renal Pharma Italia S.r.l. Sales, marketing and distribution Administrative and management service providers
Netherlands NL CSL Behring BV Seqirus Netherlands B.V. Vifor Pharma Nederland B.V. Vifor Fresenius Medical Care Renal Pharma Nederland B.V. Sales, marketing and distribution Research and development Administrative and management service providers
Panama PA CSL Behring Panama S.A. Sales, marketing and distribution
Poland PL CSL Behring sp. z o.o. Sales, marketing and distribution
Portugal PT CSL Behring, Unipessoal, Lda Vifor Pharma Portugal, S.A. Sales, marketing and distribution Administrative and management service providers
Romania RO Vifor Pharma Romania S.R.L. Sales, marketing and distribution Administrative and management service providers
Russia RU Vifor Pharma RUS Limited Liability Company Vifor (International) AG - Russia branch Sales, marketing and distribution Administrative and management service providers
Slovakia SK CSL Behring Slovakia sro Administrative and management service providers
Spain ES CSL Behring, S.A. Seqirus Spain, S.L. Vifor Pharma España, S.L. Sanifit Therapeutics, S.A. Vifor Fresenius Medical Care Renal Pharma España, S.L. Sales, marketing and distribution Administrative and management service providers
Sweden SE CSL Behring AB Vifor Pharma Nordiska AB Iscotec AB Sales, marketing and distribution Administrative and management service providers
Turkey TR CSL Behring Biyoterapi llac Dis Ticaret AS Sales, marketing and distribution

Section 4. Omitted information

Information omitted (if any) for this financial year
Information omittedInformation omitted, other tax jurisdictionsExplanation of reason for omission of information
No information omitted.No information omitted.Not applicable
Disclosure of information omitted for previous financial years
No information omitted.

Section 5. Explanations for material discrepancies between income tax paid and accrued

Explanation of any material discrepancies between income tax paid and accrued
See CSL tax transparency report.

Conclusion

Basis of preparation Data in this report relates to CSL Limited and its controlled entities (the CSL Group), based on IFRS accounting standards using data sourced from CSL’s global financial and reporting systems. In accordance with EU reporting requirements, information is presented separately for each EU Member State with certain non-EU jurisdictions disclosed separately where required. All other jurisdictions are aggregated into ‘Rest of World’. This report has been prepared in compliance with EU public Country-by-Country reporting requirements. It is relevant to note that: • Data is presented on an aggregated jurisdictional basis and will not be directly comparable to CSL Group consolidated financial disclosures. • Financial data is presented in USD currency. • Financial disclosures are derived from aggregation of data for individual entities that are tax resident (or have a branch located) in that jurisdiction, excluding any group consolidation or elimination adjustments. • The report does not provide a full representation of CSL’s global economic footprint or value chain and should be read in conjunction with CSL’s FY25 Annual Report and Tax Transparency Report for further context. Notes on specific disclosures: • Total revenues include income earned by entities in that jurisdiction, from both related and external unrelated parties. • Profit (loss) before income tax excludes intercompany dividends. • Income tax paid reflects cash taxes paid during the financial year by entities in that jurisdiction to local revenue authorities, including withholding taxes paid to foreign governments in respect of income earned (where applicable). • Income tax accrued is based on current tax expense recognised in the period for entities in the jurisdiction (excluding deferred tax or prior year related tax expense amounts). Utilisation of previously unrecognised tax losses may result in tax expense rates differing from statutory tax rates. • Number of full-time equivalent employees does not include contingent workers, with the data sourced from CSL’s internal employee management systems.